Abstract
We wish to report a serious problem in the ADVIA:Centaur® chemiluminescence assay for cobalamin (Bayer Diagnostics; formerly the ACS:Centaur® assay, Chiron Diagnostics). The problem is urgent for two reasons: (a) our findings suggest that many cobalamin-deficient patients are being missed; and (b) the assay is used by increasing numbers of laboratories, which some time ago abandoned radioisotopic methods and were recently faced with the withdrawal of widely used assays by Abbott Laboratories. Several months after our hospital’s clinical laboratory introduced the Centaur assay, we noted that the number of subnormal results being reported had declined from ∼15–20 to 4–5 per month. When we reassayed two serum specimens that had given subnormal cobalamin results with the Abbott IMx® method earlier and had been stored at −20 °C, the results obtained with the Centaur method were within reference values. As a result of these observations, we selected 33 sera from our research collection of specimens that had been assayed with our radioisotope dilution assay (RIDA) …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
